Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug493 | BNT162b2 Wiki | 0.58 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.58 |
| D016472 | Motor Neuron Disease NIH | 0.58 |
| D012598 | Scoliosi NIH | 0.23 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.58 |
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.58 |
Navigate: Correlations HPO
There is one clinical trial.
It is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
Description: Volume of distribution (Vt) in different brain regions for each [11C]-PBR28 PET scan, and change after BLZ945 treatment, compared to baseline. Evaluate brain microglial reduction, as measured by reduction in TSPO binding following oral doses of BLZ945 in ALS participants by using PET imaging with [11C]-PBR28.
Measure: Change from baseline in volume of distribution (Vt) in different brain regions for [11C]-PBR28 PET scan Time: Day -42, up to Day 22Description: Measured by Cmax - The maximum plasma concentration of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - Cmax Time: Day 1; up to Day 17Description: Measured by Tmax - Time to Reach the Maximum Concentration After Drug Administration of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - Tmax Time: Day 1; up to Day 17Description: Measured by AUC - Area under the curve of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - AUC Time: Day 1; up to Day 17Description: Measured by T1/2 - The elimination half-life of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - T1/2 Time: Day 1; up to Day 17Description: Urine renal clearance (CLR) of BLZ945
Measure: Renal Clearance (CLR) of BLZ945 Time: Day 1; up to Day 7Description: To assess the CYP2C8 pharmacogenomic-pharmacokinetic relationship; CYP2C8 genotyping and BLZ945 plasma PK parameters
Measure: CYP2C8 genotyping and BLZ945 plasma PK parameters Time: Day 1; up to Day 17Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports